Enliven Therapeutics ($ELVN) Insider Trading & Smart Money Activity
Enliven Therapeutics, Inc. ($ELVN) has 4 insider trades, 2 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 4 insiders sold ($40.18M), net -$40.18M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 4
- Net insider $ (12 mo)
- -$40.18M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 2
ELVN insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 1 · $39.01M | 0 / 0 | 2 / 0 |
| Q3 2026 | 0 | 2 · $554.76K | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $606.72K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ELVN insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Garland J. ScottDirector | Sell (Open-market sale) | 13K sh | $606.72K | -12.1% | — | |||||
| Insider | Hohl BenjaminCHIEF FINANCIAL OFFICER | Sell (Open-market sale) 10b5-1 | 6.02K sh | $303K | -10.1% | — | |||||
| Insider | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell (Open-market sale) 10b5-1 | 5K sh | $251.75K | -10.1% | — | |||||
| Analyst | Stifel | Reiterates to buy | PT $80 | +4.2% | +12.4% | Read | |||||
| Analyst | Jones Trading | Reiterates to buy | PT $70 | -1.7% | +4.2% | Read | |||||
| Insider | Orbimed Advisors LLC | Sell (Open-market sale) | 860.12K sh | $39.01M | +10.6% | +15.0% | — | ||||
| 13F | Baker Bros. Advisors | Added | +633.78K sh | $45.94M | +0.5% | +2.5% | Read | ||||
| 13F | Baker Bros. Advisors | Added | +633.78K sh | $36.22M | +0.5% | +2.5% | — |
1W / 1M / 6M = how ELVN moved from the trade or filing date.
Insider trading in ELVN: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Garland J. Scott | Director | 1 | -$606.72K | Oct 1, 2026 | |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | 1 | -$303K | Sep 17, 2026 | |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | 1 | -$251.75K | Sep 17, 2026 | |
| Orbimed Advisors LLC | 1 | -$39.01M | Jun 22, 2026 |
Institutions moving ELVN (13F)
Analyst ratings on ELVN
Frequently asked questions
Are ELVN insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 4 insiders made 4 open-market sales worth $40.18M, a net -$40.18M.
What is the latest insider trade in ELVN?
Garland J. Scott, Director filed a sell (open-market sale) of 13K sh worth $606.72K on Oct 1, 2026.
Which institutions changed their ELVN positions?
Recent 13F filers moving the stock include Baker Bros. Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.